Abstracts Archive - Page 2489 of 2607 - ACR Meeting Abstracts

Abstract Number: 1730 • 2012 ACR/ARHP Annual Meeting
Antiphosphatidylethanolamine Is Not Associated with Thrombosis or Pregnancy Loss in Systemic Lupus Erythematosus
Ehtisham Akhter¹, Hong Fang², Nathalie Bardin³, Marielle San Marco³ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Hopital de la Conception, Marseille, France
Background/Purpose: Phosphatidylethanolamine, a zwitterionic phospholipid, is a major component of the cell plasma membrane. Phospatidylethanolamine exerts both anticoagulant and procoagulant activities in different conditions. The…
Abstract Number: 1731 • 2012 ACR/ARHP Annual Meeting
IgA Anti-β₂glycoprotein I Antibodies Are Pathogenic in a Mouse Model of APS
Patricia Ruiz Limon¹, Zurina Romay-Penabad², Ana Laura Carrera Marin³, Elizabeth Papalardo⁴ and Silvia S. Pierangeli³, ¹Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Rheumatology/Dept Int Med, Univ of TX Medical Branch, Galveston, TX, ³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴Louisville APL Diagnostics, Inc, Seabrook, TX
Background/Purpose: Recently exclusive IgA anti-b2Glycoprotein I (ab2GPI) seropositivity - in the absence of any other antiphospholipid (aPL) antibodies- has been reported particularly in SLE patients. …
Abstract Number: 1732 • 2012 ACR/ARHP Annual Meeting
Annexin A5 Resistance Identifies a Subset of Thrombosis Patients in Systemic Lupus Erythematosus
Ehtisham Akhter¹, Hong Fang², Xiao Xuan Wu³, Jacob Rand⁴ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Pathology; Hematology Laboratories, Montefiore Medical Center, Bronx, NY, ⁴Montefiore Medical Center, Bronx, NY
Background/Purpose: Annexins are a family of structurally related proteins that bind to phospholipids in a calcium dependant manner. Annexin A5 (AnxA5), present on the surfaces…
Abstract Number: 1733 • 2012 ACR/ARHP Annual Meeting
Effect of Hydroxychloroquine (HCQ) On the Annexin A5 Resistance Assay (AnxA5-RA) in Antiphospholipid Antibody (aPL)-Positive Patients: Preliminary Results of an Ongoing Prospective Study
Alana B. Levine¹, Jacob H. Rand², Xiao Xuan Wu³, JoAnn Vega⁴, Glendalee Ramon¹, Stephen L. Lyman⁴, Doruk Erkan¹ and Michael D. Lockshin⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Pathology; Hematology Laboratories, Montefiore Medical Center, Bronx, NY, ³Pathology; Hematology Laboratories, Montefiore Medical Center, Bronx, NY, ⁴Research, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: One proposed mechanism of aPL-mediated thrombosis is disruption of the AnxA5 shield, allowing initiation of coagulation reactions on phospholipid surfaces. The AnxA5-RA measures the…
Abstract Number: 1734 • 2012 ACR/ARHP Annual Meeting
Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities
Savino Sciascia¹, Veronica Murru¹, Giovanni Sanna², Dario Roccatello³, Munther A. Khamashta⁴ and Maria Laura Bertolaccini¹, ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: The clinical accuracy of testing for antiphospholipid antibody (aPL) both, as individual tests and/or in combination, is still being investigated. We aimed to identify…
Abstract Number: 1735 • 2012 ACR/ARHP Annual Meeting
Independent Validation of the Antiphospholipid Score (aPL-S) for the Diagnosis of Antiphospholipid Syndrome (APS)
Savino Sciascia¹, Maria Laura Bertolaccini¹, Dario Roccatello² and Munther A. Khamashta³, ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ³Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: The so called “antiphospholipid score (aPL-S)” was recently developed and validated (1). This score was shown to be a useful quantitative index for diagnosing…
Abstract Number: 1736 • 2012 ACR/ARHP Annual Meeting
The Estimated Prevalence of Antiphospholipid Antibodies in the General Population with Pregnancy Morbidity
Cecilia B. Chighizola¹, Guilherme Ramires de Jesus², Laura Andreoli³, Alessandra Banzato⁴, Guillermo J. Pons-Estel⁵, Michael D. Lockshin⁶, Doruk Erkan⁷ and On Behalf of APS Action⁸, ¹Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ²Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Rheumatology Unit, University of Brescia, Brescia, Italy, ⁴Department of Cardiac Thoracic and Vascular Sciences, (2) Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua Italy, Padua, Italy, ⁵Servicio de Enfermedades Autoinmunes, (4) Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, ⁶Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸APS ACTION, New York, NY
Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international research network created to conduct well-designed clinical trials in persistently…
Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Sima Ahadieh¹, Tina Checchio¹, Thomas Tensfeldt¹, Jonathan French², Sriram Krishnaswami¹, Richard Riese³, Sujatha Menon¹, Mary G. Boy¹ and Jamie L. Geier⁴, ¹Pfizer Inc., Groton, CT, ²Metrum Research Institute, Tariffville, CT, ³Pfizer Inc, Groton, CT, ⁴Epidemiology, Pfizer Inc., New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…
Abstract Number: 1698 • 2012 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologics in 2,281 US Patients with Rheumatoid Arthritis
Sofia Ramiro¹, Frederick Wolfe², David J. Harrison³, George Joseph³, David H. Collier³, Désirée van der Heijde⁴, Robert Landewé⁵ and Kaleb Michaud⁶, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Amgen Inc., Thousand Oaks, CA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Identifying predictors of discontinuation of biologic treatment for Rheumatoid Arthritis (RA) has clinical and research importance given the chronicity of RA and high costs…
Abstract Number: 1699 • 2012 ACR/ARHP Annual Meeting
Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events : Date From the Autoimmunity and Rituximab Registry
Jean Hugues Salmon¹, Patrice Cacoub², Bernard G. Combe³, Jean Sibilia⁴, Beatrice Pallot Prades⁵, Olivier Fain⁶, Alain G. Cantagrel⁷, Maxime Dougados⁸, Olivier Meyer⁹, Philippe Carli¹⁰, Edouard Pertuiset¹¹, Isabelle Pane¹², Philippe Ravaud¹³, Xavier Mariette¹⁴ and Jacques-Eric Gottenberg¹⁵, ¹Rheumatology, Reims, France, ²Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ³Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ⁵Rheumatology department, Saint Etienne university hospital, Saint Etienne, France, ⁶Internal Medicine, Jean Verdier Hospital, Bondy, France, ⁷Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁸Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁹Rheumatology, Hopital Bichat, Paris, France, ¹⁰HIA sainte Anne, Toulon, France, ¹¹Rheumatology, Ch Rene Dubos, Pontoise, France, ¹²Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁵Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Limited data are available regarding the proportion and severity of late onset neutropenia after RTX in large and unselected populations of patients with various…
Abstract Number: 1700 • 2012 ACR/ARHP Annual Meeting
Prevalence of Spondyloarthritis in Anterior Uveitis Patients: The Sentinel Study
Miguel Cordero Coma¹ and Xavier Juanola², ¹Department of Ophthalmology, Unidad de Uveítis. Hospital Universitario de León, León, Spain, ²Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: Anterior uveitis (AU) is the most common form of uveitis in western countries with an annual incidence rate of about eight new cases for…
Abstract Number: 1701 • 2012 ACR/ARHP Annual Meeting
Validation of the New ASAS Criteria for Classification of Early Spondyloarthritis in the Esperanza Cohort
Eva Tomero¹, Loreto Carmona², Juan Mulero³, Eugenio De Miguel⁴, Milena Gobbo⁵, Carmen Martínez⁶, Miguel A. Descalzo⁶, Pedro Zarco⁷, Eduardo Collantes-Estevez⁸ and Esperanza Group⁹, ¹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Health Sciences School, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, ⁴Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Research Unit, Spanish Society of Rheumatology., Madrid, Spain, ⁶Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁷Unit Rheumatology, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, ⁸Depatamento de Medicina, IMIBIC-Reina Sofia Hospital, Cordoba 14012, Spain, ⁹Madrid
Background/Purpose: To validate the new axial and peripheral ASAS criteria in patients with early spondyloarthritis (SpA) and the full spectrum of clinical manifestations under clinical…
Abstract Number: 1702 • 2012 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Blocking Agents Inhibit the Progression of Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis
Alper M. van Sijl¹, Izhar C. van Eijk², Mike J.L. Peters³, Erik H. Serne³, Yvo M. Smulders⁴ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ⁴Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is associated with an increased cardiovascular (CV) risk that might be due to the chronic underlying inflammatory process. It is still…
Abstract Number: 1703 • 2012 ACR/ARHP Annual Meeting
Relationship Between Tobacco Smoking and Radiographic Spinal Progression in Axial Spondyloarthritis: The Role of Inflammatory Activity
Denis Poddubnyy¹, Hildrun Haibel², Joachim Listing³, Elisabeth Märker-Hermann⁴, Henning Zeidler⁵, Jürgen Braun⁶, Martin Rudwaleit⁷ and Joachim Sieper⁸, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Dr. Horst Schmidt Kliniken, Wiesbaden, Germany, ⁵Medizinische Hochschule, Hannover, Germany, ⁶PsAID taskforce, EULAR, Zurich, Switzerland, ⁷Endokrinologikum Berlin, Berlin, Germany, ⁸Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: Cigarette smoking is associated with functional impairment [1, 2] and radiographic severity of ankylosing spondylitis (AS) [3, 4]. Moreover, smoking status at baseline was…
Abstract Number: 1704 • 2012 ACR/ARHP Annual Meeting
New Threshold Values for Spinal Mobility Measures Based On a Large Nationally Representative Sample of U.S. Adults Ages 20-69 Years
Shervin Assassi¹, Michael H. Weisman², Zhongxue Chen³, Mohammad Rahbar³ and John D. Reveille⁴, ¹Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Univ of Texas Health Science Center at Houston, Houston, TX, ⁴Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Spinal mobility measures are widely utilized for diagnosis and assessment of disease severity in patients with Ankylosing Spondylitis. The previously proposed threshold values for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].